BACKGROUND: Despite the availability of a variety of effective drugs, Inadequate control of blood pressure is common. Thereare some indications that the angiotensin-converting enzyme (ACE) gene modifies the response to antihypertensive drugs,but the results have beeninconclusive. OBJEC11VE: ToInvestigate whether theinsertion/deletion polymorphism of the ACEgenemodifies blood pressure differences among subjects using diuretics,~-bl ockers, calcium-channel antagonists, or ACEinhibitors.
hibitors, 3 studies indicated that subjects with the D allelehada stronger drugeffect,8·10 2 indicated theI allele hada strongereffect,6,7 and 4 found no drug-gene effect. 3 -S ,t1 No drug-gene interaction wasfound in studies of subjects using -bl ockers. 4, 12 Due to conflicting results, it remains unclear whether the IJD polymorphism of the ACE gene influences the response to ACEinhibitors or~-bl ockers.
Diuretics and calcium-channel antagonists are also influenced by the RAS (ie, by the counter regulatory system). For example, diuretic therapy leads to salt loss, which in turn results in volume depletion, causing an increase in plasmarenin activity,"Calcium-channel antagonistsblock the inwardmovement of calcium by binding to L-type calcium channels in the heartand in smoothmuscle of the coronaryand peripheral vasculature. This could result in activation of the RAS. IS The purpose of this study was to evaluate the relationship between the lID polymorphismof the ACE gene on the mean difference in systolicblood pressure (SBP) and diastolic blood pressure (DBP) among subjects who used diuretics,~-bl ockers, calcium-channel antagonists, and/or ACE inhibitors.
Methods

SElTING
The Rotterdam Studystarted in 1990as a population-based, prospective, follow-up study.All 10275 residentsof the Rotterdam suburbof Ommoordwho were 55 years or older were invitedto participate. The aim of the Rotterdam Study was to investigate determinants of disease occurrence and progression in the elderly. Our study was approvedby the Medical EthicsCommiueeof Erasmus University and conducted in compliance with their requirements. In total,7983 (78%)residents gave written informed consent and.of 6869(86%). the ACEgenotype wasassessed. Baseline measurements weretakenuntil 1993. The design of this population-based studyhasbeendescribed elsewhere."
The baselineexaminationincludedan interviewon demographics, current healthstatus. medical history, family history of diseases. smoking habits. and current use of medication. During a physicalexamination. bloodpressure. weight. and heightwere measured and bloodwas drawn for DNAextraction. Bloodpressure was measured. withsubjects in a sitting position. at the right upper arm with a random-zero sphygmomanometer. The average of the 2 measurements. separated by a countof pulserate. was used in the analysis. All participants were subsequently examined every 2-3 years (1993-1995. 1997-1999) . Blood pressure data fromall 3 examinations wereusedin thisstudy.
Pharmacyrecordswere availablefor approximately 99% of the cohort as of January I. 1991. These recordsincludethe nameof the drug. the day of dispensing. the dosageform. the numberof units dispensed. theprescribed dailydose(POD), and the Anatomical Therapeutic Chemicalcodeof the drug. 17 • 18 
COHORT ANDOUTCOME DEFINITION
The studypopulation included all individuals in the Rotterdam Study who had hypertension. for whom the ACE genotypewas assessed. and for whomone or morebloodpressure measurements wereavailable. We defined hypertension as one or morebloodpressure measurement(s) dur-ing follow-up that met one of the following criteria: SBP 160mm Hg or higherand/orDBP 95 mm Hg or higher. Subjectswho used antihypertensive drugsduring follow-up werealsodefined as hypertensive: When a blood pressure measurementwas taken. we assessed whethera prescription wasfilled by thepharmacy on thesameday. Theduration of each prescription wascalculated by dividing the number of dispensed tablets or capsules by theprescribed dailynumber. Whenthe measurement date fell within the usageperiod, the subjectwasconsidered as currently exposed. When morethan oneantihypertensive drugclass wasusedat the timeof the blood pressure measurement, themeasurement wasexcluded.
Antihypertensive drug treatment wasclassified into4 groups: diuretics.~-bl ockers.
calcium-channel antagonists, and ACE inhibitors. Subjects could switch betweenno treatmentand differentantihypertensive drug classesand between different antihypertensive drug classes. Due to smallnumbers for otherantihypertensive drug classes.only subjects using drugsfrom the 4 groupslistedabove were included in the analysis. Pharmacyrecordswere availableas of January I. 1991.Nevertheless, bloodpressure measurements from 1990were included if an individual did not use an antihypertensive drug,according to a self-reported questionnaire. and did not startantihypertensive therapy beforeJuly I, 1991. according to the pharmacy dispensing records. The end of the studyperiod wassetat December 31. 1999.
POTENTIAL CONFOUNDERS ANDEFFECT MODIFIERS
The potential confounders considered were age; gender;body mass index(BMI); defined dailydose (DOD);examination time (1st, 2nd. or 3rd);smoking at baseline; history of myocardial infarction; diabetes mellitus at baseline;current use of nitrates,statins, or nonsteroidal antiinflammatory drugs; use of anotherantihypertensive drug class 2 weeks priorto thebloodpressure measurement; useof an antihypertensive drug for 6 of the8 weekspriorto the bloodpressure measurement; andthecumulative numberof days an antihypertensive was used. Historyof myocardial infarction was self-reportedand confirmed by a physicianor demonstrated on a baselineelectrocardiogram. To comparedosagesof different antihypertensive drugs, we used the POD expressed as the numberof ODDsper day. The DODis defined as the average dailydose for the main indication in an adult weighing 70 kg." ODDs providea fixed unit of measurement independent of price and formulation, enablingthe researcher to assess trendsin drug consumption and perform comparisons amongpopulation groups.
Smoking was considered an effectmodifier sincesmoking and the 0 allelehavebeenassociated withincreased generation of angiotensin 11. 19 
GENOTYPE
The I and 0 allele of the ACE gene were identifiedon the basis of polymerase chain reaction (PCR) technique in accordance with the method described by Lindpaintner et al.,'?withsome modifications. Because the 0 allele in heterozygous samples is preferentially amplified. there is a tendency toward misclassification of 4-5% of the ID to DO genotypes. For this reason. a secondPCR was performedwitha primer pair that recognizes an insertion-specific sequence(5'TGG GAC CAC AGC GCC CAC TAC3' and 5'TCG CCA GCC ere CCA TGC CCA genotypes. Tocompare thedifference in ODDs foreachexamination, an ANOVA wasused, stratified by genotype. A marginal, generalized,linear model wasused to investigate anyassociation between IIDpolymorphismof theACEgeneandantihypertensive treatment for 2 outcomes: mean difference in SSP andDBP. A P valueof 0.05or lesswasconsidered statistically significant. Sincesubjects could have I, 2, or 3 measurements, thegeneralized linear model wasused to account forintrapersoncorrelations among repeated measurements. Thecovariance matrix of the repeated dependent measurements was unstructured, and data wereanalyzed usingSASstatistical software andcorrected forpotential confounders. Weperformed 2 analyses. In the first, we compared the meanSBP and DSP levelsamongthe different genotype groups (DO,10, II) for untreated andtreated patients. Thereference group consisted of untreated subjects withtheDDgenotype.
In the second analysis, we focused on the drug-geneinteraction by comparing the meanSBP and DBP levelsamongthe different genotype groups forsubjects using thesame antihypertensive drugclass. The reference group consisted ofsubjects with theDDgenotype whohada prescription fortheantihypertensive drug class inquestion. Themean SSP and DSP of treated subjects were defined asthemean SSP or DBPof subjects whoused theantihypertensive drug class in question minus themean sap orDBPin untreated subjects with thesame genotype.
Results
Of the 6869 subjects who participated in the Rotterdam Study between January 1, 1990, and December 31, 1999, 3025 were classified as hypertensive and had a total of 6500 blood pressure measurements. In total, 28.3%, 51.4%, and 20.3% had the DD, 10, and II genotypes, respectively. Of this population, 431 used diuretics (603 measurements), 745 used f3-blockers (1078 measurements), 306 used calcium-channel antagonists (400 mea-surements), and 317 used ACE inhibitors (420 measurements). A person could switch from one antihypertensive drug class to another.Baseline characteristics at the first examination are presented in Table 1 . The mean ± SD DDD values at baseline for diuretics were0.81 ± 0.44, for f3-blockers 0.67 ± 0.17, for calcium-channel antagonists 0.79 ± 0.43, and for ACE inhibitors 1.01 ± 0.63. During the firstexamination round, 855 subjects weretreated with an antihypertensive. During the 3 examination rounds, there was no statistically significant difference in the DDDs among the genotype groups for any of the antihypertensive drugclasses listedabove.
In the univariate analysis, withoutcorrection for potential confounders, none of the antihypertensive drug classes was associated with a significant decrease in the mean difference in SBP or DBP for the 3 genotype groups (datanot shown). After adjustment for potential confounders, the ACE gene did not significantly influence the mean difference in SBP (10 vs DD =0.42 mm Hg, 95% CI -5.18 to 6.01; II vs DD = -1.67 romHg, 95% CI -9.60 to 6.27) or DBP (ill vs DD =-0.21 mm Hg, 95% CI -3.24 to 2.82; II vs DD =-0.84 mm Hg, 95% CI -5.19 to 3.51) when all antihypertensive drugswere combined. The adjusted mean difference in SBP and DBP is shown in Figures 1 and 2 , with the mean SBP or DBP levels in untreated subjects withthe DD genotype as a reference. Subjects with theDD genotype who used diuretics had a 5.19 mm Hg (95% CI -10.16 to 0.78) lower mean SBP and 0.44 mm Hg (95% CI -3.76 to 2.88) lowermeanDBP compared withuntreated subjects with the samegenotype. 
Effect ofDrug-Gene Interaction on Antihypertensive Therapy
Our findings in a white population suggest that the ACE liD polymorphism does not influence the mean SBP or DBP difference in subjects usingdiuretics,~-bl ockers, calcium-channel antagonists, or ACE inhibitors, even after correcting for the DDD and otherpotential confounders.
Previous studies investigating the possible interaction between the lID polymorphism and antihypertensives on bloodpressure response have been inconclusive>" Of the 8 studies thatinvestigated the interaction between the ACE gene andACE inhibitors on SBP and DBP in hypertensive patients, 3 suggested that the D allele had a strongerdrug effect,8-lo while 2 indicated the I alleles? and 4 found no difference between the 2 alleles. 3 -5,1I Regarding -bl ockers, 2 studiesfound no drug-gene interaction effect on blood pressurev" and one found an interaction with thiazide diuretics." In that study, peopleon diuretics with one or 2 copiesof the I alleleof the ACE gene and one copy of the 460Trp allele of the a-adducin gene showed the largest decrease in blood pressure.
The primary difference betweenthose studies and ours is that ours was observational and previous studies were nonrandornized trials. In trials, treatment groups can be standardized with respect to dose, medication, duration of therapy, and time between blood pressure measurementand medication intake. In addition, it is possible that, in our study, the medicationtakenat the timeof bloodpressure measurement was not the initial drug chosen, but rather an alternative that, through a processof trial and error, was found to be the most effective. The potential overrepresentation of good responders increased the chance of finding a drug-gene interaction.
One strength of an observational study is that it resembles daily clinical practice, and analysiscan be adjusted to account for potential confounders, such as dose and durationof therapy. Another strength of this study was the largesamplesize. However, a limitation is that no baseline measurement immediately preceding the commencement of an antihypertensive drug was available, and measurements were only takenevery2-3 years, making it impossible to calculate the immediateeffect after ad-drug-gene interactions in smokers. However, none was found withany of the antihypertensive drug classes in current smokers (datanot shown). cca =calcium-channel antagonists. 1 =DOuntreated; 2 =10untreated; 3 =II untreated; 4 =00 diuretics;5 =10diuretics;6 =II diuretics;7 =DOl3-blockers; 8 =lOll-blockers; 9 =II l3-blockers; 10 =DOcalcium-channel antagonists; 11 =IDcalcium-channel antagonists; 12 ="calcium-channel antagonists; 13 =DOACE inhibitors; 14 =10ACE inhibitors; 15 =" ACE inhibitors. cca =calcium-channel antagonists. 1 = ODuntreated; 2 =10untreated; 3 =II untreated; 4 = DOdiuretics;5 = 10diuretics;6 =II diuretics;7 =ODl3-blockers; 8 =lOll-blockers; 9 = II l3-blockers; 10 =DOcalcium-channel antagonists; 11 =10calcium-channel antagonists; 12 =II calcium-channel antagonists; 13 =DOACE inhibitors; 14 =10ACE inhibitors; 15 =II ACE inhibitors.
In addition, we investigated whetherthere was an interaction between the ACE lID polymorphism and diuretics, -bl ockers, calcium-channel antagonists, and/or ACE inhibitors ( Figure 3 ). The reference in this analysis was the meanSBP or DBP of subjects with the DD genotype using the investigated antihypertensive drug. Diuretic users with the II genotype had a 0.23 mm Hg (95% CI -5.48 to 5.94) higher mean SBP and 0.81 mmHg (95% CI -4.14 to 2.52) lower mean DBP compared with diuretic users with the DD genotype.
After adjustment for the covariates, there was only a trend toward an association with the II genotype versus the DD genotype in patients treated with a~-bl ocker (p = 0.096). However, therewas no dose-response relationship withregard to bloodpressure withthe I allele.
In addition, becauseprevious research in the Rotterdam Studyfound a smoking-dependent effectof the ACE gene on blood pressure in smokers," our study assessed the www.theannals.com
The Annals of Pharmacotherapy • 2006 February, Volume 40 • 215 ministration of an antihypertensive drug. Therefore, shortlivedand temporary interactions weremissed in this study. Other limitations were the absenceof a clinicallyconfirmed diagnosis of hypertension and the overrepresentation of subjects withisolated systolic hypertension (-50% of untreatedpts.). Given that the mean age of treated patients exceeded 70 years, it is reasonable to assume that thereis also an overrepresentation of patients withisolated systolic hypertension in thisgroup. Thus, the results cannot be generalized to all patients withhypertension.
Another potential limitation of our study is thatwe considered only one genetic polymorphism, which is linked to serum ACE activity but remains controversial in hypertension. Zhu et apz found 2 other ACE gene mutationsthat were linkedwith blood pressure and ACE serumconcentrations. Therefore, it mightbe necessary to typeadditional markers.
Finally, observational studiesmay be vulnerable to selection, information, and confounding bias. Confounding is unlikely given that the data were adjusted for potential confounders, but it is impossible to adjustfor unmeasured confounders. Race could have been an additional confounder; however, considering that less than 1% of the subjects had a differentethnic background, it is unlikely that this biased our results. More than 99% of our study population was white, so results can onlybe generalized to thatrace. Othervariables existthathavean impact on blood pressure, suchas exercise. Therefore, it is possible that we over-or underestimated the bloodpressure-lowering effect of the antihypertensive drugclasses. However, sincethisis likelythe same for the various genotypes, this has not influenced the results of the drug-gene interaction.
Difference in blood pressure between treated and untreated patients couldbe the resultof confounding by indication. Because a physician is free to chooseeithera particularantihypertensive drug or no treatment, specific patient characteristics may have influenced this decision. Therefore, we investigated the mean difference in blood pressure between usersof the same antihypertensive drug therapysince they were most likely to have the same patientcharacteristics.
Information bias is also unlikely, as data on drug exposure were prospectively gatheredvia computerized pharmacies in a similar and unbiased fashion for all subjects. It is possible, however, thatwe under-or overestimated baselinecharacteristics for which we usedself-reported data. In addition, we assumedthat all prescribed pills were taken and thus may have overestimated adherence. Because this variable is likely the samefor all 3 genotypes, it is unlikely to have biased our results. Selection bias is unlikely becausethis study was population based and loss to followup wasnegligible.
Conclusions
The caveats notwithstanding, our study suggests thatthe ACE lID polymorphism of the ACE gene does not influence the mean blood pressure difference among users of low-ceiling diuretics, p-blockers, calcium-channel antagonists, or ACE inhibitors. Although it appears that the ACE lID polymorphism does not have clinical relevance in the response to antihypertensive drugs, further investigations of short-and long-term outcomes are needed to reach definitive conclusions. 
